Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.

  title={Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.},
  author={P. Barton Duell and Francine K. Welty and Michael Miller and Alan Chait and Gmerice Hammond and Zahid S. Ahmad and David E. Cohen and Jay D. Horton and Gregg S. Pressman and Peter P. Toth},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  • P. Duell, F. Welty, P. Toth
  • Published 14 April 2022
  • Medicine, Biology
  • Arteriosclerosis, thrombosis, and vascular biology
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is believed to affect >25% of adults worldwide. Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition. Hepatic complications from NAFLD include nonalcoholic steatohepatitis, hepatic cirrhosis, and hepatocellular… 

New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis

This narrative review aims to examine the available data on CAD seen in patients with NAFLD, to outline the main directions undertaken by the CVD risk assessment and the multiple putative underlying mechanisms implicated in the relationship between CAD and NAFLd, and to raise awareness about this underestimated association between two major, frequent and severe diseases.

Epidemiological trends and clinical characteristic of NAFLD/MAFLD in Asia

The prevalence of NAFLD in Asia is above the global average, and has become the most common cause of CLD in most Asia countries, with the increasing urbanization, dietary Westernization, and sedentary lifestyle.

Ectopic Fat and Cardiac Health in People with HIV: Serious as a Heart Attack

This study aims to summarize knowledge of alterations in adipose tissue distribution among people with HIV (PWH), with a focus on the cardiac depot and how this relates to the known higher risk of

Potential Effects of Icosapent Ethyl on Cardiovascular Outcomes in Cigarette Smokers: REDUCE-IT Smoking.

In REDUCE-IT, IPE treatment was associated with reduced risk of CV events in current and former smokers to levels observed in never smokers, raising the possibility that IPe treatment may attenuate CV hazards attributable to smoking.

Cardiovascular disease risk stratification in type 2 diabetes

The study, which examined 9 risk factors, provides insights into which risk factors were associated with MACE outcomes in this cohort and evaluation and validation of QRISK2 score and type 2 diabetesspecific cardiovascular risk tools in those with type 2 diabetes is limited.

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

NAFLD and atherosclerotic cerebrovascular risk are linked to stroke in children under the age of 18 and the risks are similar to that of adults aged between 18 and 25.

Glycation and a Spark of ALEs (Advanced Lipoxidation End Products) – Igniting RAGE/Diaphanous-1 and Cardiometabolic Disease

It is proposed that upon the consumption of high fat/high sugar diets, the production of receptor for advanced glycation end products (RAGE) ligands and DAMPs, contribute to the development of foam cells, endothelial injury, vascular inflammation, and, ultimately, atherosclerosis and its consequences.

Management of NAFLD in primary care settings

  • V. WongS. Zelber-Sagi J. Lazarus
  • Medicine
    Liver international : official journal of the International Association for the Study of the Liver
  • 2022
The role of primary care in the management of non-alcoholic fatty liver disease is reviewed, especially the involvement of dietitians and physical activity trainers in lifestyle intervention, as well as initiating the discussion of bariatric surgery in patients with severe obesity.